Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.58 |
| ▸ | BRAF | P15056 | 8/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.52 |
| ▸ | CSNK1G2 | P78368 | 4/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13861947 | 0.90 | KDR (0.61) | RAF1BRAFKDRCSNK1DCSNK1G2 | |
| SCHEMBL4367856 | 0.85 | KDR (0.55) | RAF1BRAFKDRCSNK1DCSNK1G2 | |
| SCHEMBL4369261 | 0.84 | CSNK1A1 (0.54) | RAF1BRAFKDRCSNK1DCSNK1A1 | |
| SCHEMBL4367761 | 0.84 | KDR (0.48) | RAF1BRAFKDRCSNK1DCSNK1G2 | |
| SCHEMBL4161669 | 0.81 | KDR (0.56) | RAF1BRAFKDRCSNK1DCSNK1G2 | |
| SCHEMBL4369908 | 0.81 | KDR (0.56) | RAF1BRAFKDRCSNK1DCSNK1G2 | |
| SCHEMBL4164763 | 0.80 | KDR (0.54) | RAF1BRAFKDRCSNK1DCSNK1G2 | |
| SCHEMBL4367201 | 0.79 | FGFR2 (0.52) | RAF1BRAFKDRCSNK1DCSNK1G2 | |
| SCHEMBL4376917 | 0.79 | BRAF (0.59) | RAF1BRAFKDRCSNK1DCSNK1G2 | |
| SCHEMBL4367608 | 0.79 | MAPT (0.52) | RAF1BRAFKDRCSNK1DCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | RAF1 1846/4885BRAF 612/4885KDR 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.